UNSPSC 51171959: Proxazole

This classification denotes an antispasmotic agent with the molecular formula C17H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FD72T13M0K, chemically known as 1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, (+)- (9ci) but generally known as proxazole, which bears US NIH Compound Identifier 8590. European Medicines Agency schedules Proxazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10146MIG. The term PROXAZOLE is an International Non-Proprietary Name.

UNSPSC 51171959 Proxazole is a Commodity code that captures pharmaceutical products, specifically proxazole and related drug compounds, procured by state and local health and criminal justice agencies for offender testing, pharmacy benefit programs, and hospital or institutional use. State and local governments buy proxazole as part of broader drug-screening panels, generic pharmaceutical inventories for state healthcare systems, and direct-to-manufacturer pharmacy programs. The issuing bodies soliciting under this code include county criminal justice departments (community supervision and corrections), state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state and local facilities.

Recent activity clusters in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, with an estimated contract value of $600,000 over two years plus three optional one-year renewals; the scope includes immunoassay screening with LC/MS/MS or GC/MS confirmation for approximately 25,031 annual tests across five- and six-panel screens, requiring lab certification from SAMHSA, Texas DPS, or CAP. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 (response deadline April 3, 2026) to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory procurement designed to inform future formal solicitations rather than commit to specific contract amounts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon; awarded vendors must supply through three authorized wholesalers with proposals weighted 75 percent on price competitiveness and the remainder on fixed pricing, administrative compliance, EDI capability, and administrative fee structure. All three solicitations reflect state and local demand for pharmaceutical screening, testing, and inventory management but show no unified award timeline or consolidated demand.